β-site APP-cleaving enzyme 2 (BACE2) is a homolog of BACE1, which is considered as the most promising therapeutic target for Alzheimer’s disease (AD). This evidence concerns the gene BACE2 and early-onset autosomal dominant Alzheimer disease.